Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-15 · accession 0001415889-25-008556 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-15 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | — | +50.0K | 165.9K | +43% | — |
| D | 2025-03-18 | 2025-03-17 | MIRM | Peetz Christopher | CEO, Dir | S - Sale+OE | $44.21 | -27.3K | 138.6K | -16% | -$1.21M |
| D | 2025-03-18 | 2025-03-15 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $0.00 | -50.0K | 25.0K | -67% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-15 | M | A | 50,000 | — | 165,920 | D | — | — | (F1) Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Common | Common Stock | 2025-03-17 | S | D | 27,279 | $44.21 | 138,641 | D | — | — | |
| 3 | Derivative | Performance Restricted Stock Units | 2025-03-15 | M | D | 50,000 | $0.00 | 25,000 | D | — · — to — | 50,000 Common Stock | (F1) Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. |